Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Arrowhead Pharmaceuticals and keeping the price target at $80.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Patrick Trucchio has given his Buy rating due to a combination of factors that highlight Arrowhead Pharmaceuticals’ growth potential. The company is advancing multiple regulatory and clinical catalysts, with plozasiran, their lead small interfering RNA (siRNA) program, nearing a commercial launch for familial chylomicronemia syndrome (FCS). The program has a PDUFA date set for November 18, 2025, and the U.S. commercial infrastructure is largely in place, with full enrollment in three global Phase 3 trials for severe hypertriglyceridemia (sHTG) completed ahead of schedule.
Additionally, Arrowhead’s pipeline is expanding with late-stage developments such as zodasiran in the pivotal Phase 3 YOSEMITE trial for homozygous familial hypercholesterolemia (HoFH) and early-stage candidates targeting obesity and Alzheimer’s disease. Strategic partnerships, including a significant milestone from Sarepta Therapeutics and collaborations with Amgen and Takeda, further validate the company’s approach. With a cash runway extending into 2028, Arrowhead is well-positioned to capitalize on upcoming value-creating events, including the anticipated U.S. approval of plozasiran and key clinical readouts across its diverse therapeutic programs.
In another report released on August 8, RBC Capital also maintained a Buy rating on the stock with a $38.00 price target.